Research

Mixed

Bariatric surgery (Roux-en-Y gastric bypass, sleeve gastrectomy, or biliopancreatic diversion) produces significantly greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome compared to non-surgical treatment (diet, behavioral therapy, or pharmacotherapy) in individuals with a BMI ≥30, with effects sustained up to two years.

For individuals with a BMI of 30 or higher, bariatric surgery (specifically Roux-en-Y, sleeve, or biliopancreatic diversion) is significantly more effective than diet and lifestyle changes alone for losing weight and reversing type 2 diabetes. While surgery carries risks like anemia or the need for reoperation, the long-term benefits for metabolic health and weight maintenance are superior to non-surgical treatments, especially for those who have failed previous weight loss attempts.

GoodSupportsHIGH confidence
Compared with non-surgical treatment of obesity, bariatric surgery leads to greater body weight loss and higher remission rates of type 2 diabetes and metabolic syndrome.
Viktoria Gloy et al. · BMJ · 2013

Why this rating

Meta-analysis of 11 RCTs, but limited by high heterogeneity, short follow-up (max 2 years), and small sample sizes.

Source

Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials

Viktoria Gloy et al. · BMJ · 2013

DOI 10.1136/bmj.f5934

Meta-analysis · 11 studiesCited 1,335×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →